Ibandronate

Generic Name: Ibandronate

Brand Names: Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva

Drug Type: Small Molecule

Chemical Formula: C_₉H_₂₃NO_₇P_₂

CAS Number: 114084-78-5

Unique Ingredient Identifier: UMD7G2653W

Background: Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
...

Indication: For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis

Associated Therapies: -

Clinical Trials

Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients

Phase 3

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Ibandronate
Drug: Vitamin Supplements

First Posted Date: 2009-01-19

Last Posted Date: 2018-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00824993

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PTH & Ibandronate Combination Study (PICS)

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: PTH(1-84)
Drug: Ibandronate
Other: Placebo injection
Other: Placebo pills

First Posted Date: 2008-05-23

Last Posted Date: 2013-11-05

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 44

Registration Number: NCT00683163

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects

Phase 2

Completed

Conditions: Post-menopausal Osteoporosis

Interventions: Drug: Ibandronate
Drug: Risedronate
Drug: Alendronate

First Posted Date: 2008-04-25

Last Posted Date: 2018-03-06

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 410

Registration Number: NCT00666627

Locations: 🇬🇧
Academic Unit of Bone Metabolism (Sheffield), Sheffield, South Yorkshire, United Kingdom

Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort

Phase 4

Withdrawn

Conditions: HIV Infections

Interventions: Drug: Ibandronate
Behavioral: Lifestyle modifications

First Posted Date: 2008-04-21

Last Posted Date: 2019-03-13

Lead Sponsor: Germans Trias i Pujol Hospital

Registration Number: NCT00662077

Locations: 🇪🇸
Germans Trias i Pujol Hospital - Lluita Sida Foundation, Badalona, Barcelona, Spain

BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.

Phase 3

Completed

Conditions: Post-Menopausal Osteoporosis

Interventions: Drug: Ibandronate

First Posted Date: 2007-10-17

Last Posted Date: 2016-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 677

Registration Number: NCT00545779

A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Placebo
Drug: ibandronate

First Posted Date: 2007-10-17

Last Posted Date: 2016-05-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT00545051

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Ibandronate

First Posted Date: 2007-10-17

Last Posted Date: 2016-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 716

Registration Number: NCT00545363

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Phase 4

Terminated

Conditions: Osteoporosis

Interventions: Drug: teriparatide
Drug: ibandronate

First Posted Date: 2007-03-13

Last Posted Date: 2014-10-29

Lead Sponsor: Papageorgiou General Hospital

Target Recruit Count: 19

Registration Number: NCT00446589

Locations: 🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece

Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.

Phase 2

Conditions: Renal Transplant

Interventions: Drug: Placebo
Drug: Ibandronate

First Posted Date: 2007-01-18

Last Posted Date: 2010-03-24

Lead Sponsor: Smerud Medical Research International AS

Target Recruit Count: 130

Registration Number: NCT00423384

Locations: 🇳🇴
Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

The Effect Of Oral Ibandronate In Male Osteoporosis

Phase 3

Completed

Conditions: Male Osteoporosis

Interventions: Drug: placebo
Drug: Ibandronate

First Posted Date: 2006-11-10

Last Posted Date: 2009-12-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 135

Registration Number: NCT00397839

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy